Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ Московский научно-исследовательский институт психиатрии Минздравсоцразвития РФ, Москва
Список исп. литературыСкрыть список 1. Аведисова А.С., Ахапкин Р.В. Проблемы клинической оценки переносимости терапии психотропными препаратами. Психиатр. и психофармакотер. Журн. им. П.Б.Ганнушкина. 2005; 1 (7): 17–20. 2. Барденштейн Л.М. Опыт применения атипичного нейролептика сероквеля для лечения первого психотического эпизода шизофрении у подростков. Психиатр. и психофармакотер. 2001; 3 (6): 213–4. 3. Бурдаков А.Н., Бурдакова Е.В., Фесенко Ю.А. Нейролептики в детской психиатрической практике. СПб.: ЭЛБИ-СПб, 2007. 4. Горобец Л.Н. Нейроэндокринные дисфункции и нейролептическая терапия. М.: Медпрактика-М, 2007. 5. Каледа В.Г., Бархатова А.Н., Стрельцова М.А. Современные подходы и принципы терапии шизофрении и шизоаффективного психоза юношеского возраста. Вопр. психического здоровья детей и подростков. 2004; 4 (2): 42–50. 6. Каледа В.Г. Терапия эндогенных приступообразных психозов юношеского возраста – основные принципы и подходы. Журн. неврол. и психиатр им. С.С.Корсакова. М.: Медиа Сфера, 2006; 106 (9): 4–11. 7. Клиническое руководство: модели диагностики и лечения психических и поведенческих расстройств. Под ред. В.Н.Краснова, И.Я.Гуровича. Сост. в Московском НИИ психиатрии Минздрава России. Соц. и клин. психиатрия (Прил.). М., 1999. 8. Козловская Г.В. Опыт пролонгированного лечения рисперидоном ранней шизофрении и аутизма у детей. Вопр. психического здоровья детей и подростков. 2008; 8 (1): 69–79. 9. Либин Л.Я., Чомская В.М., Лесникова С.А. и др. Оценка эффективности, безопасности и переносимости препарата Ридонекс у больных с параноидной формой шизофрении. Психиатр. и психофармакотер. 2011; 13 (6): 30–4. 10. Мамцева В.Н. Детская и подростковая психиатрия. М.: Медицина, 2003. 11. Северный А.А., Шевченко Ю.С., Волошин В.М. Проблема эффективности и безопасности современной психофармакотерапии детей и подростков. Вопр. психического здоровья детей и подростков. 2004; 4 (2): 39–42. 12. Ястребов Д.В. Терапия обсессивных и тревожных расстройств у больных с непсихотическими формами шизофрении. Психиатр. и психофармакотер. 2011; 13 (4): 38–47. 13. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiat 2010; 22 (5): 417–28. 14. Aichhorn W, Whitworth AB, Weiss EM. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 2006; 29 (7): 587–98. 15. Cadenhead KS. Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiat Res 2011; 188 (2): 208–16. 16. Carlisle LL, McClellan J. Psychopharmacology of schizophrenia in children and adolescents. Pediatr Clin North Am 2011; 58 (1): 205–18. 17. Correll CU. Symptomatic presentation and initial treatment for schizophrenia in children and adolescents. J Clin Psychiat 2010; 71 (11): e29. 18. Correll CU, Kratochvil CJ, March JS. Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiat 2011; 72 (5): 655–70. 19. Dassori AM, Copeland LA, Zeber JE et al. Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia. Psychiatr Serv 2011; 62 (1): 47–53. 20. Davidson M, Caspi A, Noy S. The treatment of schizophrenia: from premorbid manifestation to the first episode of psychosis. Dialogues in clinical neuroscience 2005; 1: 7–16. 21. Diflorio A, Jones J. Is sex important? Gender differences in bipolar disorder. Int J Psychiatr 2010; 22 (5): 437–52. 22. De Rivera JL, Lal S, Ettegi P et al. Effects of acute and chronic neuroleptic therapy in serum prolactin level in men and women of different age groups. Clin Endocrinol 1976; 5 (3): 273–82. 23. Felmet K, Zisook S, Kasckow JW. Elderly patients with schizophrenia and depression: diagnosis and treatment. Clin Schizophr Relat Psychoses 2011; 4 (4): 239–50. 24. Fleischhacker WW. Treatment of first episode of schizophrenia. Eur Psychat 2002; 17 (Suppl. 4): 371–5. 25. Fulton MM, Allen ER. Polypharmacy in the eldery: a literature review. J Am academy of nurse practitioners 2005; 17 (4): 123–32. 26. Groleger U, Novak-Grubic V. Gender, psychosis and psychotropic drugs: differences and similarities. Psychiatr Danub 2010; 22 (2): 338–42. 27. Grunder G, Wetzel H, Schlosser R. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiat 1999; 45 (1): 89–97. 28. Haack S, Seeringer A, Thürmann PA et al. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenom 2009; 10 (9): 1511–26. 29. Jalenques I, Rachez C, Tourtauchaux R et al. Old patients suffering from long-standing schizophrenia: clinical aspects. Geriatr Psychol Neuropsychiatr Vieil 2011; 9 (3): 345–53. 30. Kasckow J, Fellows I, Golshan S et al. Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response. Am J Geriat Psychiat 2010; 18 (9): 853–7. 31. Keers R, Aitchinson KJ. Gender differences in antidepressant drug response. Int J Psychiat 2010; 22 (5): 485–500. 32. Kipke DM et al. Adolescent development and the biology of puberty: summary of a workshop on new research. Washington: National Academy of Science 1999; p. 12. 33. Koch-Weser J, Sellers EM, Zacest R. The ambiguity of adverse drug reactions. Eur J Clin Pharmacol 1977; 11: 75–8. 34. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of drug reactions I. Background, description and instructions for use. JAMA 1979; 242: 623–32. 35. Levine J, Schooler N. Strategies for analyzing side effects data from SAFTEE. Psychopharmacol Bull 1986; 22: 343–81. 36. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand 2000; 401: 3–38. 37. Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs 2011; 71 (2): 179–208. 38. Meyers BS, Jeste DV. Geriatric psychopharmacology: evolution of a discipline. J Clin Psychiat 2010; 71 (11): 1416–24. 39. Moriarty PJ, Lieber D, Bennett A et al. Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr Bull 2001; 27 (1): 103–13. 40. Parker G, Brotche H. Gender differences in depression. Int Rev Psychiat 2010; 22 (5): 429–36. 41. Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 24, 94 (5A): 2–12. 42. Rado J, Janicak PG. Aripiprazole for late-life schizophrenia. Clin Interv Aging 2010; 7 (5): 253–8. 43. Ribolsi M, Magni V, Rubino IA. Quetiapine fumarate for schizophrenia and bipolar disorder in young patients. Drugs Today (Barc) 2010; 46 (8): 581–7. 44. Robinson B. Brest changes in the male and female with chlorpromazine or reserpine Therapy. Med J Aust 1957; 44: 239–41. 45. Rost K, Hsieh YP, Xu S et al. Potential disparities in the management of schizophrenia in the United States. Psychiatr Serv 2011; 62 (6): 613–8. 46. Saad MF, Damani S, Gingerich RL. Sexual dimorphism in plasma leptin concentration. J Clin Endocrinol Metab 1997; 82: 579–84. 47. Sable JA, Jeste DV. Antipsychotic treatment for late-life schizophrenia. Current Psychiat Reports 2002; 4: 299–306. 48. Salem JE, Kring AM. The role of gender differences in the reduction of etiologic heterogeneity in schizophrenia. Clin Psychol Rev 1998; 18 (7): 795–819. 49. Smith S. Gender differences in antipsychotic prescribing. Int Rev Psychiat 2010; 22 (5): 472–84. 50. Suzuki T, Remington G, Uchida H et al. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging 2011; 28 (12): 961–80. 51. Szymanski S, Lieberman JA, Alvir JM et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiat 1995; 152 (5): 698–703. 52. Talaslahti T, Alanen HM, Leinonen E. Severe psychoses in the elderly – schizophrenia and delusional disorder. Duodecim 2011; 127 (4): 375–82. 53. Tsuboi T, Suzuki T, Uchida H. A tipping point in drug dosing in late-life schizophrenia. Curr Psychiat Rep 2011; 13 (3): 225–33. 54. Von Bahr C, Wiesel FA, Movin G et al. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. Psychopharmacol (Berl) 1991; 103 (4): 443–8. 55. Weizman R, Weizman A, Levi J et al. Sexual dysfunction associated with hyperprolactinemia in males and females undergoing hemo dialysis. Psychosom Med 1983; 45: 259–69. 56. Wiffen BD, Rabinowitz J, Fleischhacker WW et al. Insight: demographic differences and associations with one-year outcome in schizophrenia and schizoaffective disorder. Clin Schizophr Relat Psychoses 2010; 4 (3): 169–75. 57. Wudarsky M, Nicolson R, Hamburger SD et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999; 9: 239–45.